This article discusses unapproved drug substances, research peptides, or compounded medications, not dietary supplements. These substances are not FDA-approved for wellness use, and FDA does not verify compounded drugs for safety, effectiveness, or quality before marketing. Do not inject, purchase, compound, or substitute unapproved peptides based on this content; consult a licensed clinician for personal medical questions.

Peptide Safety Research

TB-500 FDA status: thymosin beta-4 fragment safety and evidence

TB-500 is commonly marketed online as a repair or recovery peptide, but FDA's safety-risk language is explicit: thymosin beta-4 fragment (LKKTETQ), also known as TB-500, raises concerns about immunogenicity, aggregation, peptide-related impurities, and missing human exposure data for drug products containing the fragment. As of May 10, 2026, FDA's safety-risk page lists thymosin beta-4 fragment (LKKTETQ), also known as TB-500, under bulk drug substances withdrawn from nomination for compounding use. FDA has also scheduled thymosin beta-4 fragment forms for discussion at the July 23, 2026 Pharmacy Compounding Advisory Committee meeting. Those documents do not make TB-500 FDA-approved, supplement-like, or safe for consumer use.

Written by Editorial Team·Status note: Legal/regulatory status checked against official FDA and anti-doping sources where relevant on May 10, 2026. This page is educational and is not medical or legal advice.·Updated May 10, 2026

This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Who this is for

This page is for readers asking whether TB-500 is FDA-approved, legal, banned in sport, or clinically proven for injury recovery.

It is also for editors checking whether evidence from thymosin beta-4 can be used on a TB-500 page. The answer is: only with careful caveats. Parent-molecule evidence and topical clinical trials do not establish that TB-500 injections are safe or effective.

How we chose the source base

We used FDA's safety-risk page for nominated and withdrawn bulk drug substances, FDA's July 2026 PCAC agenda, and the WADA 2026 Prohibited List as the regulatory anchors. We then reviewed PubMed-indexed thymosin beta-4 clinical literature to understand what has been studied in humans and where that evidence does not transfer cleanly to TB-500.

We intentionally avoided vendor pages, clinic pages, dosing forums, and affiliate sources.

Evidence snapshot

FDA says it has not identified human exposure data for drug products containing thymosin beta-4 fragment (LKKTETQ), also known as TB-500. FDA also flags immunogenicity risk due to potential aggregation and peptide-related impurities. FDA's current public page places the substance in the withdrawn-nomination section rather than an approval or general-use pathway.

Human studies of thymosin beta-4 include topical ophthalmic and venous-ulcer contexts, not consumer TB-500 recovery injections. Those studies are relevant to the biology of thymosin beta-4, but they do not prove safety or efficacy for TB-500 as sold online.

Safety notes

The biggest editorial risk is evidence transfer. A study of topical thymosin beta-4 solution in dry eye is not a study of injectable TB-500. A venous-ulcer trial design is not a proof of sports recovery benefit. Route, molecule, manufacturing, sterility, dose, and population all matter.

The gray-market risk is also material. Products marketed for research may be used by consumers despite lacking the controls expected for approved drug products.

Alternatives

For injury recovery, the appropriate alternative is evaluation by a qualified clinician, evidence-based rehabilitation, load management, and approved treatments when indicated. For athletes, NSF Certified for Sport supplements are a lower-risk supplement category than unapproved peptide products, but supplements still require careful review.

Publication status note

Legal/regulatory status checked against official FDA and anti-doping sources where relevant on May 10, 2026. This page is educational and is not medical or legal advice. The page remains non-promotional, does not provide dosing, sourcing, injection, stacking, or protocol advice, and should be rechecked before major FDA or WADA updates.

Official source documents

These official sources should be rechecked before publication.

Source	U R L
FDA - Safety risks and withdrawn nomination status for thymosin beta-4 fragment (LKKTETQ), also known as TB-500	https://www.fda.gov/drugs/human-drug-compounding/safety-risks-associated-certain-bulk-drug-substances-nominated-use-compounding
FDA - July 23, 2026 Pharmacy Compounding Advisory Committee agenda	https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
FDA - Bulk drug substances used in compounding	https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding
WADA - 2026 Prohibited List	https://www.wada-ama.org/en/prohibited-list

Common Questions

Frequently Asked Questions

Is TB-500 FDA-approved?

No. TB-500 is not FDA-approved for recovery, injury repair, bodybuilding, anti-aging, or wellness use. FDA identifies safety concerns, withdrawn nomination status, and a pending July 2026 advisory-committee discussion for thymosin beta-4 fragment (LKKTETQ), also known as TB-500.

Can thymosin beta-4 studies prove TB-500 works?

No. They can provide biological context, but they cannot establish that a different fragment, route, dose, formulation, or gray-market product is safe or effective for human recovery.

Why does FDA mention no human exposure data?

FDA's statement means it lacked important human-use information for drug products containing the TB-500 fragment when assessing the nominated bulk substance. That is a safety uncertainty, not proof of safety.

Can athletes use TB-500?

Athletes should treat TB-500 as prohibited. The WADA 2026 Prohibited List names thymosin-beta4 derivatives such as TB-500 under S2.3, which is prohibited at all times.

Primary Sources

Citations & Research

[1]Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) modelSource
[2]Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healingSource
[3]The effect of thymosin treatment of venous ulcersSource